Ascentage Pharma Presents at ASH 2025
Ascentage Pharma Group International Inc. (NASDAQ: AAPG), a prominent biopharmaceutical company focused on innovative cancer therapies, has announced its participation at the 67th American Society of Hematology (ASH) Annual Meeting. The event will feature groundbreaking results from clinical studies involving the company's novel drug, lisaftoclax (APG-2575), alongside other investigational drug candidates.
About Lisaftoclax
Lisaftoclax is an orally available Bcl-2 inhibitor that shows promise in treating hematologic malignancies and certain solid tumors. The drug is already making strides in China following approval from the National Medical Products Administration (NMPA) for treating adults with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have undergone at least one systemic therapy, including Bruton's tyrosine kinase (BTK) inhibitors.
Latest Presentation Details
At ASH 2025, Ascentage Pharma will deliver an oral presentation showcasing the latest findings from a registrational Phase II study of lisaftoclax monotherapy in patients with relapsed/refractory (R/R) CLL/SLL. Furthermore, a poster presentation will be available highlighting results from the combination of lisaftoclax with azacitidine (AZA) in patients with newly diagnosed or previously venetoclax-exposed myeloid malignancies.
The Significance of ASH 2025
The ASH Annual Meeting is one of the largest platforms for presenting the latest research in hematology. It enables researchers, clinicians, and industry professionals to come together, share findings, and discuss collaborations aimed at addressing cancer treatment challenges. The forthcoming meeting will be held in Orlando, Florida, both online and in-person from December 6-9, 2025.
Insights from Dr. Yifan Zhai
Dr. Yifan Zhai, the Chief Medical Officer of Ascentage Pharma, expressed enthusiasm about the presentation: "Lisaftoclax has shown promising efficacy and an acceptable safety profile in various trials. Its inclusion in ASH 2025 presentations demonstrates the drug's potential significance in hematological treatments. We are committed to progressing our clinical development programs to provide more options for patients who need them."
Overview of Studies on Lisaftoclax
Ascentage Pharma’s presentations will feature significant studies focusing on the efficacy and safety of lisaftoclax, including:
- An oral presentation detailing results from a registrational Phase II study targeting R/R CLL/SLL patients.
- A poster presentation examining the effectiveness of combining lisaftoclax with azacitidine in challenging cases of myeloid malignancies.
Clinical Insights on Efficacy and Safety
Preliminary data from the recent studies highlight the drug's capabilities. In a pivotal Phase II trial, the objective response rate among R/R CLL/SLL patients was a notable 62.5%. Safety profiles indicated manageable adverse events, primarily hematologic toxicities, but no treatment-related fatalities were reported. Moreover, remarkable responses were observed, including minimal residual disease negativity in a segment of patients.
Projected Future Developments
Ascentage Pharma is actively pursuing further research into its drug portfolio, emphasizing the potential for improving treatment paradigms within hematology. The excitement surrounding the upcoming ASH presentation illustrates the company’s continuous commitment to innovation and addressing the unmet medical needs of cancer patients.
Outreach and Collaboration
The company has engaged in partnerships with numerous global biopharmaceutical firms to enhance the development of its innovative therapies. These collaborations focus on leveraging advanced research techniques and tapping into a diverse range of clinical insights that can play a critical role in the ongoing fight against cancer.
Frequently Asked Questions
What is ASH 2025?
ASH 2025 is the annual meeting of the American Society of Hematology where new research on blood diseases, particularly cancer, is presented.
What will Ascentage Pharma present at the conference?
Ascentage Pharma will present data on its Bcl-2 inhibitor, lisaftoclax, including results from clinical studies involving its use in CLL/SLL and myeloid malignancies.
What is the significance of lisaftoclax?
Lisaftoclax is significant due to its efficacy in treating hematological cancers, particularly in patients who have not responded well to other therapies.
Who is Dr. Yifan Zhai?
Dr. Yifan Zhai is the Chief Medical Officer of Ascentage Pharma, overseeing clinical development and research efforts.
Why is the ASH meeting important?
The ASH meeting is essential as it gathers global experts to share the latest findings in hematology, fostering collaboration and innovation in cancer treatment.
